Lipid Updates From Spring 2019

Slides:



Advertisements
Similar presentations
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Advertisements

The Latest Lipid Guidelines:
PCSK9 Inhibitors and Cardiovascular Outcomes Trials
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA
PCSK9 Inhibitors Post-CVOTs
Statin Selection in the Elderly
Current Dyslipidemia Management Guidelines Residual Risk.
An Endocrinology Clinic in Dyslipidemia
Diabetes and Dyslipidemia
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.
Cardiovascular Disease Risk Reduction Advances in Dyslipidemia
Cholesteryl Ester Transfer Protein Inhibitors
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Patient 1: 53-Year-Old Man With CVD Risk Factors
Select Topics in Cardiovascular Medicine
American Heart Association Scientific Sessions
Obesity and Dyslipidemia: How Would You Treat?
Advances in Dyslipidemia: What Have We Learned From ACC 2017
Statins and the Elderly Patient
Statin Selection in Special Patient Populations: A Case Challenge
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Beyond Statin Therapy.
LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Statin Class in Session
An Update on PCSK9 Inhibitors
Evaluating LDL-C Recommendations
New Pathways in Lipid Care
What's New in Dyslipidemia?
62-year-old Man With Unstable Angina
Statin Class in Session
Personalizing Statin Therapy in Patients With HIV
PCSK9 Inhibitors and Cardiovascular Outcomes
% decrease in LDL-C at 24 weeks from baseline
PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?
Improving Appropriate Access to PCSK9 Inhibitors
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
Statins and HIV:.
New LDL-C Lipid Targets
A PCP's Guide to Dyslipidemia
Radical New Concepts in Lipid Management
Clinicians' Corner in Dyslipidemia
Updates in Cardiovascular Medicine
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.
Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.
PCSK9 Mutations PCSK9 Loss-of-function Mutations.
Glucose Management and Statin Therapy
LDL Cholesterol.
How to Optimize Cholesterol Management in High-Risk CV Patients
Latest Lipid Guidelines in Perspective
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Reducing Risk for CV Outcomes
New Lipid-Lowering Guidelines
New Lipid-Lowering Therapies
An Update on PCSK9 Inhibitors
Omega-3s vs Pure EPA in Clinical Practice
PCSK9 Inhibitors and Statin Intolerance
Updates on Dyslipidemia
Achieving Lipid Targets With PCSK9 Inhibition
Lipids, the Heart, and the Kidney
in diabetic patients with mixed dyslipidemia
PCSK9 Inhibitors and Real-World Evidence
Shared-Decision Making in Dyslipidemia
Presentation transcript:

Lipid Updates From Spring 2019

Burden of Dyslipidemia in ASCVD

Lessons From Statin Trials

Nonstatin Strategies to Further Reduce LDL-C Ezetimibe

Nonstatin Strategies to Further Reduce LDL-C PCSK9 Inhibitors

Need for Effective Lipid-Lowering Therapy Beyond a Statin and Challenges Associated With Statin Therapy

Statins Foundation of Lipid-Lowering Therapy

Lessons Learned From the PCSK9 Inhibitor CV Outcomes Trials

PCSK9 Inhibitors are Efficient at Lowering LDL-C

PCSK9 Inhibitors Reduce CV Events

PCSK9 Inhibitors Are Safe

PCSK9 Inhibitors Reported a Clinical Benefit Associated With Very Low LDL-C Levels

Re-Evaluating LDL-C Targets

Lipid-Lowering Therapy

CLEAR Wisdom Trial Bempadoic Acid

CLEAR Wisdom Trial Results

ORION-4 Design

VESALIUS-CV Trial Design

Implications for Clinical Care

Identifying Which Patient Will Benefit Most From PCSK9 Inhibition

2018 Guidelines on the Management of Blood Cholesterol Secondary Prevention -- PCSK9 Inhibitors

Overcoming Access Barriers to PCSK9 Inhibitors

Abbreviations

Abbreviations (cont)